BWS = Beckwith-Wiedemann syndrome, IC1 = imprinting center 1, IC2 = imprinting center 2, pUPD = paternal UniParental Disomy, LOM = loss of methylation, GOM = gain of methylation, AFP = alphafetoprotein (H19/IGF2:IG-DMR) hypermethylation subgroup (28%) and pUPD subgroup (16%) and were lower in the KCNQ1OT1:TSS-DMR (IC2) subgroup (2.6%), CDKN1C (6.9%) subgroup, and the group in whom no molecular defect was detectable (6.7%). Wilms tumors (median age 24 months) were frequent in the IC1 (24%) and pUPD (7.9%) subgroups.
We obtained clinical and molecular data in our cohort of children with BWS, including tumor occurrences, and correlated phenotype and genotype. We obtained similar data from larger cohorts reported in literature.
Phenotype, genotype and tumor occurrence were available in 229 own patients. Minor differences in phenotype existed depending on genotype/epigenotype, similar to earlier studies. By adding patients from the literature we obtained data on genotype and tumor occurrence of in total 1971 BWS patients. Tumor risks were the highest in the IC1 (H19/IGF2:IG-DMR) hypermethylation subgroup (28%) and pUPD subgroup (16%) and were lower in the KCNQ1OT1:TSS-DMR (IC2) subgroup (2.6%), CDKN1C (6.9%) subgroup, and the group in whom no molecular defect was detectable (6.7%). Wilms tumors (median age 24 months) were frequent in the IC1 (24%) and pUPD (7.9%) subgroups.
Hepatoblastoma occurred mostly in the pUPD (3.5%) and IC2 (0.7%) subgroups, never in the IC1 and CDKN1C subgroups, and always <30 months of age. In the CDKN1C subgroup 2.8% of patients developed neuroblastoma.
We conclude tumor risks in BWS differ markedly depending on molecular background. We propose a differentiated surveillance protocol, based on tumor risks in the various molecular subgroups causing BWS. associated with an increased risk to develop embryonic tumors. 1, 2 The prevalence at birth is estimated to be 1/12,000. 3 Two sets of similar but not identical diagnostic criteria are mainly used in clinical practice (Table I) . 4, 5 Familial transmission has been reported as occurring in ∼15 percent of BWS patients if all patients were grouped together. 6 BWS exhibits etiologic molecular heterogeneity due to a variety of alterations in growth regulating genes located at chromosome 11p15. This chromosome region harbors two independently regulated clusters of imprinted genes ( Fig. 1 ).
One cluster contains the reciprocally imprinted genes IGF2 and H19 and is under control of H19/IGF2:IG-DMR (IC1), upstream of the H19 promoter. 7 This imprinting center is differentially methylated, methylation being present only at the paternal allele. The second cluster contains (among others) the maternally expressed CDKN1C gene and the paternally expressed KCNQ1OT1 (LIT1) gene and is under control of KCNQ1OT1:TSS-DMR (IC2), located upstream of the KCNQ1OT1 promoter. This region is methylated on the maternal allele only. The majority of BWS patients (80%) show an aberrant imprinting in either one, or both imprinted clusters (choufani 2013). 8 Aberrant methylation of both ICs is typically explained by a paternal UniParental Disomy (pUPD) of the 11p15 region (20% of BWS cases). Mutations in CDKN1C are found in approximately 5-10% of (mostly familial) cases.
Infrequently paternal trisomy of 11p15 or a maternal balanced translocation involving the area causes BWS. Approximately 10-15% of cases remain without molecular confirmation of the syndrome despite carrying all clinical characteristics of the syndrome. Here we report on studies in a large cohort of BWS individuals, summarize their phenotype, add data from similar studies in literature in order to correlate the phenotype with the various genetic subgroups in BWS. We determined the relative tumor risks for each of these subgroups, and propose a tumor surveillance system. 
METHODS

Patient selection
The Academic Medical Center in Amsterdam started to offer cytogenetic and molecular diagnostics tests for BWS in the early nineties. Since 2000 it functions as the national center of referral for individuals with BWS. Any patient who fulfilled the diagnostic criteria described by DeBaun and/or Elliott (Table I ) was allowed to enter the study, irrespective whether the clinical diagnosis BWS could be confirmed molecularly or not. 4, 5 Clinical data of all included patients were obtained either directly by examining patients, or through questionnaires on clinical manifestations forwarded to physicians who submitted samples of patients suspected for having BWS. In 2005 a dedicated outpatient clinic was opened specifically for individuals with BWS. A single clinical geneticist (SMM) evaluated all individuals referred to this clinic, and extensive initial and follow-up data were collected.
For the present study the Dutch Childhood Oncology Group pediatric was consulted in June 2015, in order to evaluate whether, since the last clinical contact, a tumor had developed in any of our patients. In all patients with a tumor the major characteristics of that tumor were obtained.
The Medical Ethics Committee of our institution approved this study (#99.15.210).
Informed consent was obtained from all participating patients and/or their parents/legal representatives.
Molecular analysis
Studies were performed at the Molecular We have carefully avoided using patient data more than once as in several publications data of earlier publications were incorporated. If needed this has been checked specifically by contacting the authors of the original publications.
Statistical analysis
The 
RESULTS
Characteristics of own study group
In total 244 patients were included in this study. Five patients had a chromosome abnormality and were excluded as the other chromosome imbalances prohibited analysis of the phenotype due to only a 11p15 imbalance. All patients but three were at least five years of age when last data were gathered (mean 15.2 years, median 13.5 years). The distribution over the four genetic subgroups is provided in Table II , in which also the frequencies of manifestations of BWS in the genetic subgroups and in the total patient group are available. The various abnormal morphological characteristics are available in Supplemental Table S-I.
Tumor frequencies in own study group and in literature cohorts
We were able to obtain reliable data on both genotype and tumor occurrence in 229 BWS patients of the present cohort (Table III) . 5, 12, 13, 16, 17, 27, 31 In three cohorts not all BWS patients were screened for CDKN1C mutations 5, 13 , and in two other studies (Brioude et al., 2013; Mussa et al., 2015) BWS patients in whom no (Table III) . In addition we studied the age at which BWS patients developed a tumor. If available both mean and median age is provided, and the highest age at which a tumor was detected per genetic subgroup (Table IV) . 30 Whether in the present cohort the specificity of either set of criteria is higher than the other remains uncertain as we have no information on how frequently samples of patients fulfilling either set of criteria are indeed submitted for molecular analysis. We found in the present study that more than half of patients (varying from 50% to 58.4%) in whom a molecular diagnosis of BWS could be made did not fulfill the Elliott criteria. As reported previously 13, 31 there is also a subgroup of patients with a clinical diagnosis of BWS but no detectable molecular abnormality. 13, 31 In this group the percentage of patient that did not fulfill the Elliott criteria (56.4%) was similar to that in the other patient groups (with a detectable molecular cause).
We conclude that the sets of diagnostic criteria are both useful, but for neither of the sets do we know with certainty that sensitivity and specificity are truly high. BWS was and still is a clinical diagnosis, in which a molecular confirmation is not always possible, and further studies of the Elliott and DeBaun criteria and other sets of criteria are needed.
Clinical features of BWS
The phenotype of the present cohort is, in general, comparable to that in patients described in other cohorts. 16, 27 As can be expected the patients in the group 'clinical diagnosis' show the (Table II) . Remarkable differences between the various groups are the lower frequency of a high birthweight in the IC2 hypomethylation subgroup, the high frequency of asymmetrical overgrowth in the pUPD subgroup (as described before) and explained by mosaicism for the pUPD), and the relatively low frequency of ear creases, ear pits and facial naevus flameus in the IC1 hypermethylation subgroup. 5, 12, 14, 16, 31, 32 Also, as reported previously, a low frequency of omphalocele in this latter subgroup was found, and less frequently an enlargement of the internal organs (especially kidney and spleen) in the IC2 hypomethylation subgroup.
32,33
Though not all data was collected by evaluating the cohort personally, the vast majority of cases were seen and examined and so the data in Table II is likely to be very reliable.
Neoplasia
In the present cohort we have found the highest risk to develop cancer in the IC1 hypermethylation subgroup, and to a lesser extend in the pUPD group. In the IC2 hypomethylation subgroup two children with a Wilms tumor were found, which has not been reported before. Niemitz et al. have described two patients with a Wilms tumor and hypomethylation of KCNQ1OT1 in normal kidney tissue and LOH in the tumor, but unfortunately details regarding methylation results in lymphocytes were not provided. 34 We provide a complete literature overview evaluating almost 2000 BWS patients, which allows reliable conclusions (Table III) . Earlier careful meta-analyses of the literature are available, but in much smaller numbers. 15, 27 We realize there is likely still a publication bias in data reported in literature, and in reality frequencies may be somewhat lower.
We evaluated the nature of the tumors in our own patients and patients reported in literature.
Wilms tumors and hepatoblastoma are only rarely present in the IC2 hypomethylation subgroup the variability in tumor types is remarkably large. In the IC1 group no hepatoblastoma has ever been described. In the CDKN1C group reported by Gaston et al. 12 and Brioude et al. 16 individuals developed neuroblastoma at age 6m and 10m, respectively.
The median age at which BWS individuals develop cancer in the present cohort has been 24 months for Wilms tumors and 12 months for hepatoblastoma. There is a tendency for Wilms tumors to develop at an earlier age in the IC2 subgroup compared to the IC1 and pUPD groups. Results are compared to literature data in Table IV .
Cancer risks in BWS have been reported correlated with the presence of hemihyperplasia, nephromegaly, nephrogenic rests and nephroblastomatosis. 1,33,35 Mussa et al. 32 found hemihyperplasia and enlarged kidneys in all patients with a Wilms tumor, and similarly DeBaun 10 reported that all patients with a Wilms tumor had enlarged kidneys if evaluated repeatedly. In this publication before molecular subgroups could be made, the nephromegaly was typically bilateral, and the cancer had always arisen in the largest kidney. 10 Gaston et al. found a (statistically insignificant) higher frequency of hemihyperplasia in patients with tumors but this was not subdivided according to molecular subtype. 12 We evaluated this in our cohort according to different molecular genetic subgroups: Wilms tumors were more frequently found in each of the genetic subgroups except for the IC2 subgroup where there is no difference (Supplemental Table S-2) . However, for none of the subgroups was this difference statistically significant. In the pUPD group there was a statistically significant increase of hemihyperplasia in the group who developed a Wilms tumor, and this was also found in the group in whom no molecular defect could be detected causing BWS. In the latter group there was also a significantly more frequent occurrence of an enlarged spleen (p=0.016). Otherwise in none of the subgroups a marked difference was 
Screening: General considerations
Screening individuals for cancer is aimed at improving the outcomes for those who have an increased genetic risk to develop tumors. 24 The outcomes can improve by detecting tumors earlier, at a less advanced stage than they would have at detection without screening. Less advanced tumors generally need less extensive surgery and less intensive chemo-and radiotherapy, and are associated with a better survival. 24 A prerequisite is that the screening schedule is as such that indeed the tumor is detected at a less advanced stage, so the velocity of the growth of the tumor, the sensitivity and specificity of the screenings procedure, the interval between the screening moments, the treatment schedules of the various stages of the tumor, and the effectiveness of these treatment schedules need to be carefully determined. The threshold level above which the risk to develop cancer is sufficiently high to provide surveillance is a subjective decision. The UK Wilms Tumor Surveillance Working
Group suggested that surveillance should be offered to children who are at a greater risk than 5% risk of Wilms tumor. 37 Other studies did not mention specifically a threshold Wilms Screening has financial implications. In most countries these are limited for the patients and their families themselves, but these may be significant for society. A costeffectiveness evaluation should be part of general evaluations of screening procedures.
38
The total of the above influences on screening should be used to weigh the potential benefits and disadvantages of any screening schedule, and to establish protocols that address adequately the needs of the population under screening. An overview of the earlier reported recommendations in BWS in which the various molecular pathogeneses have been taken into account, is provided in Table V .
Background for Wilms tumor screening
Wilms tumors are embryonal kidney tumors that are almost invariably present before 10 years of age. 19 The 
Background for hepatoblastoma screening
Hepatoblastomas are malignant liver cancers that consist of fetal liver cells, more mature liver cells and bile duct cells. 48 Ninety percent of hepatoblastomas occur before the age of four years, at a mean age of 22 months and median age of 16 months, and only exceptionally at an older age. 49 In BWS all hepatoblastoma occurred <30months of age (Table IV) . 50 We have been unable to find a reliable description of an exception. In children with BWS it was shown that hepatoblastoma was diagnosed at a significantly younger age (median age 6 months) compared to children with hepatoblastoma without BWS (median age 16 months), and also the stage at diagnosis tended to be lower. 50 All patients are treated with chemotherapy and a surgical resection is attempted after tumor shrinkage. 24 After complete resection patients have an event-free survival of > 90%. 51 Patient with tumors that are initially non-resectable have an event-free survival rate of <70%, and those with metastases have an event-free survival rate of 20-30%. 51, 52 Thus, early detection by effective screening could lower tumor advancement and treatment-related morbidity. 50, 53 In over 96% of patients with hepatoblastoma serum alpha- hepatoblastoma who were screened for recurrences. 56 They found that AFP was elevated 1-11months before the tumor was detected by the surveillance imaging, and also reported false positive results. A similar study showed AFP to be elevated until two months before imaging showed an abnormality, and these authors reported on false negative results. 57 The half-life of AFP is 5-6 days. 58 Hepatoblastoma can grow very rapidly, doubling time has been reported as low as a few weeks. 22 Authors of several early publications have concluded the usefulness of AFP screening should be doubted due to interpretation difficulties, 59 uncertainty whether it allows discovery of hepatoblastoma at such an earlier age that this changes prognosis, the relatively low occurrence of hepatoblastoma in BWS individuals, and the need for very frequent sampling for AFP for a potentially useful surveillance.
16,22,59
Background for neuroblastoma screening
Neuroblastoma is a common pediatric cancer arising from the developing sympathetic nervous system, and can follow a highly variable course, from spontaneous regression to aggressive metastatic tumors. Neuroblastoma are usually diagnosed between 0 and 4 years of age (median 19 months). 60 Less than 5% occur at 10 years of age or above. 61 
Screening proposal
The earlier suggested surveillance protocols for individuals with BWS in which molecular subgroups were taken into account, are summarized in Table V . They differ in screening methods, frequency and duration. We add to these an amended surveillance protocol based on:
a. The marked differences of occurrence of tumors in the various molecular genetic subgroups which indicate that the molecular background needs to be taken into account.
b. Screening is indicated in BWS patients with a IC1 hypermethylation, pUPD, and no detectable molecular abnormality, but not in BWS patients with a IC2 hypomethylation as in the latter patients the risk to develop a tumor is 2.6%. Raising the awareness of physicians in charge of BWS individuals with a IC2 epimutation that there is only a small increased chance of developing a tumor is indicated.
c. The number of reported BWS patients with a CDKN1C mutation is too low to determine the risk for tumor development in general, and for separate risks for Wilms tumors, hepatoblastoma, and neuroblastoma with certainty. We suggest to offer screening to the families, with a full explanation of the benefits and drawbacks. If a family decides for tumor screening we suggest to offer a complete screening. For Wilms tumor and hepatoblastoma the screening can therefore be the same screening as for BWS patients with a pUPD. Two additional studies describing larger series of patients with CDKN1C have been reported, including the occurrence of tumors, increasing the number of CDKN1C patients to 93, while the number of patients with cancer remained 6 (6.4%). 67, 68 This may indicate that if a sufficiently large number of BWS patients with a CDKN1C mutation are reported, the tumor risk may be below 5% and surveillance may not be indicated. We also realize no screening protocol will detect every tumor and occasionally a tumor will develop in a BWS child in whom surveillance is discontinued; this is an inescapable characteristic of screening if the screening procedure has disadvantages as well, which is invariably the case.
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CONCLUSIONS
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